Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Pathology Department, Vall d'Hebron Hospital, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.
J Mol Med (Berl). 2020 Feb;98(2):161-177. doi: 10.1007/s00109-020-01874-2. Epub 2020 Jan 22.
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian selection landscape between clonal tumor cell populations and the tumor microenvironment. Understanding the involved drivers and functional consequences of such tumor heterogeneity is challenging but also promises to provide novel insight needed to confront the problem of therapeutic resistance in tumors.
在这篇综述中,我们强调了肿瘤内异质性的作用,重点探讨了这一现象在临床和生物学方面带来的影响。肿瘤内异质性是通过复杂的遗传、表观遗传和蛋白质修饰产生的,这些修饰驱动了表型选择,以应对环境压力。从功能上看,异质性赋予了肿瘤显著的适应性。这种适应性范围广泛,包括细胞之间的互利合作,促进了生长和转移等特征的发展,以及克隆细胞群体在特定条件下(如缺氧或化疗)的狭窄逃避和存活,这些克隆细胞群体已经适应了在特定条件下生存。这些动态的细胞间相互作用是由克隆肿瘤细胞群体和肿瘤微环境之间的达尔文选择景观所指导的。理解这种肿瘤异质性的相关驱动因素和功能后果是具有挑战性的,但也有望为应对肿瘤治疗抵抗问题提供所需的新见解。